Svetlana Sadekova
Overview
Explore the profile of Svetlana Sadekova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
2098
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tran T, Grein J, Selman M, Annamalai L, Yearley J, Blumenschein W, et al.
Mol Ther Oncol
. 2024 May;
32(2):200807.
PMID: 38745749
V937 is an investigational, genetically unmodified Kuykendall strain of coxsackievirus A21, which has been evaluated in the clinic for advanced solid tumor malignancies. V937 specifically infects and lyses tumor cells...
2.
Tan T, Zybina Y, McKenna C, Olow A, Rukmini S, Wong M, et al.
Front Oncol
. 2022 Dec;
12:1016307.
PMID: 36531014
Introduction: Colorectal cancer (CRC) is largely refractory to currently available immunotherapies such as blockade of programmed cell death protein-1 (PD-1). Results: In this study, we identified SPATA2 and its protein...
3.
Guelen L, Fischmann T, Wong J, Mauze S, Guadagnoli M, Babala N, et al.
J Immunother Cancer
. 2022 Sep;
10(9).
PMID: 36100308
Background: Immune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement...
4.
Georgiev P, Muise E, Linn D, Hinton M, Wang Y, Cai M, et al.
Mol Cancer Ther
. 2021 Dec;
21(3):427-439.
PMID: 34965960
Targeting the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway with immunotherapy has revolutionized the treatment of many cancers. Somatic tumor mutational burden (TMB) and T-cell-inflamed gene expression profile (GEP)...
5.
Wang Y, Cui L, Georgiev P, Singh L, Zheng Y, Yu Y, et al.
Oncoimmunology
. 2021 Apr;
10(1):1896643.
PMID: 33796403
Prostaglandin E (PGE), an arachidonic acid pathway metabolite produced by cyclooxygenase (COX)-1/2, has been shown to impair anti-tumor immunity through engagement with one or more E-type prostanoid receptors (EP). Specific...
6.
Hutchins B, Starling G, McCoy M, Herzyk D, Poulet F, Dulos J, et al.
Mol Cancer Ther
. 2020 Apr;
19(6):1298-1307.
PMID: 32229606
The programmed cell death 1 (PD-1) pathway represents a major immune checkpoint, which may be engaged by cells in the tumor microenvironment to overcome active T-cell immune surveillance. Pembrolizumab (Keytruda®,...
7.
McLeod R, Angagaw M, Baral T, Liu L, Moniz R, Laskey J, et al.
Oncotarget
. 2018 Oct;
9(77):34459-34470.
PMID: 30349641
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) has been reported to mediate both tumorigenic and anti-tumor effects . Blockade of the CEACAM1 signaling pathway has recently been implicated as a...
8.
Zamarin D, Ricca J, Sadekova S, Oseledchyk A, Yu Y, Blumenschein W, et al.
J Clin Invest
. 2018 Oct;
128(11):5184.
PMID: 30277478
No abstract available.
9.
Zamarin D, Ricca J, Sadekova S, Oseledchyk A, Yu Y, Blumenschein W, et al.
J Clin Invest
. 2018 Mar;
128(4):1413-1428.
PMID: 29504948
Intralesional therapy with oncolytic viruses (OVs) leads to the activation of local and systemic immune pathways, which may present targets for further combinatorial therapies. Here, we used human tumor histocultures...
10.
Peterson V, Zhang K, Kumar N, Wong J, Li L, Wilson D, et al.
Nat Biotechnol
. 2017 Aug;
35(10):936-939.
PMID: 28854175
We present a tool to measure gene and protein expression levels in single cells with DNA-labeled antibodies and droplet microfluidics. Using the RNA expression and protein sequencing assay (REAP-seq), we...